Form 4: Bausch + Lomb Director Russel C. Robertson Receives Significant RSU Grant

Bausch + Lomb Corporation's Director, Russel C. Robertson, was granted 20,338 restricted share units as part of the company's annual incentive plan for non-employee directors.

Summary

• Russel C. Robertson, a Director of Bausch + Lomb Corporation (BLCO), acquired 20,338 common shares.
• This acquisition occurred on May 27, 2025, and was reported via a Form 4 filing.
• The shares were acquired at a price of $0, indicating a grant rather than a cash purchase.
• The transaction represents an annual grant of restricted share units (RSUs) to non-employee directors under the Bausch + Lomb Corporation 2022 Omnibus Incentive Plan, as amended and restated.
• Following this transaction, Mr. Robertson directly beneficially owns 64,914 common shares.
• The granted RSUs are scheduled to vest immediately prior to the next annual meeting of shareholders.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects a routine, expected equity grant to a director, aligning their interests with shareholders. It's not a 'strong buy' signal but a positive indicator of standard corporate governance and incentive alignment.

Positives

• The grant of 20,338 restricted share units to Director Russel C. Robertson aligns his financial interests with those of shareholders, as the value of these units is directly tied to the company's stock performance.
• The transaction is part of the company's established 2022 Omnibus Incentive Plan, indicating a structured and transparent approach to director compensation.
• The increase in director ownership demonstrates continued commitment and confidence in the company's future.

Future Outlook

The restricted share units granted to Director Russel C. Robertson are scheduled to vest immediately prior to the next annual meeting of shareholders, indicating a future increase in his vested shareholdings and continued alignment with long-term company performance.

Industry Context

This Form 4 filing details a routine equity grant to a non-employee director, which is a common practice across industries, including the healthcare and pharmaceutical sectors, to align director incentives with shareholder interests. It does not provide broader industry-specific context beyond Bausch + Lomb's internal compensation practices.

Comparison to Industry Standards

• The grant of restricted share units (RSUs) to non-employee directors is a standard compensation practice in publicly traded companies, aligning director incentives with long-term shareholder value.
• This aligns with typical corporate governance standards for director remuneration in the healthcare and pharmaceutical sectors, where equity-based compensation is prevalent to foster long-term commitment and performance.

Corporate Governance

Related Party Transactions

• The acquisition of 20,338 common shares by Director Russel C. Robertson is an equity grant under the company's 2022 Omnibus Incentive Plan, representing a routine compensation transaction with a related party (director).

Stakeholder Impact

• Shareholders: The equity grant to a director aligns their financial interests with shareholder value creation, potentially fostering better long-term decision-making and commitment from the board.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• The vesting of the 20,338 restricted share units immediately prior to the next annual meeting of shareholders.

Key Dates

Recommendation

Keywords

Bausch + Lomb, BLCO, Form 4, SEC filing, insider transaction, director compensation, restricted share units, RSU, equity grant, beneficial ownership